WVE
Wave Life Sciences Ltd
NASDAQ · Pharmaceuticals
$13.45
+0.70 (+5.49%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 141.59M | 102.39M | 447.46M | 444.96M | 373.67M |
| Net Income | -126,810,220 | -82,534,855 | 99.90M | 100.99M | 106.69M |
| EPS | — | — | — | — | — |
| Profit Margin | -89.6% | -85.1% | 22.3% | 22.7% | 28.6% |
| Rev Growth | +38.3% | +38.3% | +2.1% | +21.0% | +12.2% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 0 | 0 | 549.30M | 610.85M | 550.85M |
| Total Equity | — | — | 1.12B | 1.16B | 1.26B |
| D/E Ratio | — | — | 0.49 | 0.53 | 0.44 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | -135,000,836 | -92,747,175 | 195.67M | 186.52M | 158.68M |
| Free Cash Flow | — | — | 120.20M | 121.04M | 98.75M |